AluYb8 insertion in the WNK1 gene is not associated with hypertension in a Russian Caucasian population
Received: September 29, 2017
Accepted: October 17, 2017
Published: October 21, 2017
Genet.Mol.Res. 16(4): gmr16039809
WNK1 (With No-lysine Kinase 1), a serine-threonine kinase, regulates blood pressure by acting on various sodium transport-related ion channels. Several studies report a link between common variants of the WNK1 gene and hypertension. No data exists on Russian populations. Our aim was to evaluate the association between the WNK1 AluYb8 polymorphism and hypertension susceptibility in a Russian Caucasian population. A total of 66 patients with arterial hypertension and 40 controls were screened by polymerase chain reaction. We evaluated the genotype distribution in the patient and control groups using a chi-square test and assessed the relationship between genotypes and hypertension. This preliminary study on a small number of individuals suggests the absence of any association between the AluYb8 polymorphism and increased blood pressure. The polymorphism therefore does not increase the risk of hypertension, and in our cohort, is not a major contributor to blood pressure variability. It is therefore not useful for evaluating predisposition to hypertension, at least in the Krasnoyarsk region
Hypertension is a public health problem with high social and economic impact, affecting about 25% of the adult population. It is a major risk factor for the development of many frequent kidney and heart diseases (Mosterd et al. 1999; Kannel 2000; Griffin 2017).
Increased blood pressure is influenced by environmental factors (i.e. salt, alcohol consumption, obesity, physical activity, and chronic stress) and has a genetic component. Indeed, genetic studies on hypertension have identified various blood pressure regulating genes, belonging mainly to pathways involved in sodium homeostasis (Lifton et al. 2001; Vehaskari 2007), and various polymorphisms that influence blood pressure (Huang et al. 2008; Munroe et al. 2013).
WNK1 (with No-lysine Kinase 1) is a serine/threonine protein kinase involved in the regulation of sodium and potassium transport in the distal convoluted tubules and cortical collecting ducts of nephrons, thereby contributing to modulation of blood pressure (Veríssimo and Jordan 2001; Wilson et al. 2001). The human WNK1 gene (29 exons) occupies ∼160 kb on chromosome 12p13 and codes for multiple transcripts initiated by various promoters (Xu et al. 2000; Wilson et al. 2001; Delaloy et al. 2003).
Various mutations in the WNK1 gene have been found to cause a rare familial hypertension and hyperkalemia syndrome (Gordon’s syndrome) (Wilson et al. 2001). In addition, several common SNPs and haplotypes of WNK1 have been associated with blood pressure and with the degree of hypertension (Tobin et al. 2005; Tobin et al. 2008; Newhouse et al. 2009; Cun et al. 2011; Putku et al. 2011). All these findings suggest that the WNK1 gene may be a key regulator of blood pressure and that increased expression of WNK1 may explain variability and susceptibility to hypertension.
In the present study, we investigated a polymorphic AluYb8 insertion in WNK1 intron 10, previously considered a potential contributor to individual variability in blood pressure in different ethnic groups across Europe (Putku et al. 2011). Our final aim was to determine whether the association with hypertension susceptibility is maintained in a Russian Caucasian cohort. A study group and a control group were screened for the polymorphic sequence by PCR.
Material and Methods
Patients and healthy subjects
Sixty-six patients with hypertension and 40 control subjects were enrolled in the study conducted by the state educational institution of higher professional education, Krasnoyarsk State Medical University, in the largest cardiology clinic in the city of Krasnoyarsk, the Regional state budgetary health care institution Krasnoyarsk Inter district clinical hospital no. 20 I. S. Berzona in the period March 2014 to April 2017. Patients had to meet the following criteria to be enrolled in the study: 1) hypertensive syndrome (except secondary hypertension); 2) age between 18 and 26 years; 3) Caucasian race; 4) written informed consent to participate in the study. Patients had to meet the following criteria: 24-hour blood pressure, systolic (day) >139 mmHg; dyslipidemia (total cholesterol >4.9 mmol/l, LDL cholesterol >3.0 mmol/l, triglycerides >1.7 mmol/l, HDL cholesterol <1.0 mmol/l); positive family history of early cardiovascular disease; adipopexia, body mass index ≥30 kg/m2); bicycle ergometry systolic blood pressure >200 mmHg. The control group was selected from members of the general population of Krasnoyarsk region (Siberia), without arterial hypertension.
Genetic screening of WNK1 intron 10 AluYb8
On the day of clinical evaluation, blood samples were collected in vials containing EDTA. DNA was extracted from 0.5 ml whole blood using an E.N.Z.A. blood DNA kit (Omega Bio-Tek; NORCROSS, GA, USA) according to the manufacturer’s protocol. PCR amplification of the fragment encompassing the polymorphism was obtained by amplifying 100 ng DNA using AmpliTaq GOLD Fast PCR Master Mix (Applied Biosystems, USA) and 10 pmol of the forward and reverse primers 5'-GGGTAACCAACCCTTGAAGTAGG-3 and 5'-GGGTACTTCTCAAGTGATTAGGAGGA-3, respectively, according to the manufacturer’s instructions. Reactions were conducted in a thermocycler (BIOER, Binjiang, China): 95°C for 10 min (initial denaturation), then 35 cycles at 95°C for 30 s (denaturation), 30°C for 30 s (annealing) and 72°C for 30 s (extension), followed by a final elongation at 72°C for 5 min. After amplification, PCR products were resolved by gel electrophoresis. The PCR fragment sizes were estimated in comparison with a 100-bp DNA ladder (Thermofisher). The expected wild type fragment had 353 bp while the polymorphic AluYb8 containing WNK1 fragment contained 640 bp.
We used the chi-square test to evaluate the distribution of polymorphic AluYb8 WNK1 in patients and controls. Deviation from Hardy-Weinberg equilibrium was tested in the control group using an online tool (the Hardy-Weinberg 2-Allele Calculator http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-alleles.html). The significance of the associations between the polymorphism and blood pressure was tested using logistic regression considering the genotype as dependent variable (Alu-dominant model, i.e. AA vs AB + BB) and age, body mass index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP) as independent variables. Statistical analysis was conducted with MedCalc software (Mariakerke, Belgium). Statistical significance was set at P value <0.05.
The general details of the 66 young adult males with arterial hypertension enrolled in this study are reported in Table 1.
|Systolic blood pressure in a day (mmHg)||142.5 ± 12.9|
|Diastolic blood pressure in a day (mmHg)||83.1 ± 8.6|
|Body mass index (kg/m2)||26.23 ± 3.99|
|Mean Age (years)||23.20 ± 2.26|
Table 1: Clinical characteristics of the cohort of patients with arterial hypertension (N = 66) recruited in this study.
When our 40 sex-matched control subjects were screened by PCR to detect the polymorphism in intron 10 of WNK1, the polymorphic allele was detected in 12 (30%) and one (2.5%) subjects in heterozygous and homozygous state, respectively. The wild-type sequence was found in 67.5% of controls. The control group was found to be in Hardy-Weinberg equilibrium with respect to the polymorphism (P = 0.81).
The same analysis on our cohort of 66 hypertensive patients detected 17 (25.8%) and 2 (3%) subjects with the polymorphic allele in heterozygous and homozygous state, respectively, while the wild-type (WT) genotype was found in 71.2% of the cohort. Figure 1 shows a representative gel electrophoresis, illustrating the polymorphic profile of some DNA samples of our patient cohort. The frequency of the AluYb8 allele in the whole cohort was 16.5%. Genotype frequencies of the WNK1 variant did not differ between patients and controls (P = 0.84).
Figure 1: Representative post electrophoresis gel of samples amplified for the AluYb8 polymorphism in the intron 10 of the WNK1 gene. Lane 2,3,7-16 shows a single amplified fragment of 353 bp representing a wildtype genotype, while lane 1,4-6 show two amplified fragments delineating the profile of a heterozygous DNA samples; in lane 17 there is the profile of a positive control (CTR), while on line 18 a wild-type control. Abbreviations: MW, 100-bp DNA ladder (Thermofisher); + DNA showing the AluYb8 polymorphism.
We compared various clinical parameters of the 66 patients in order to determine whether the presence or absence of the polymorphic AluYb8 allele in WNK1 could be associated with differences in mean systolic or diastolic blood pressure over the period of a day (Table 2).
|Blood pressure in a day (mmHg)|
|Genotype||N||Mean systolic blood pressure||Mean diastolic blood pressure|
Table 2: Mean diastolic and systolic blood pressure values in a day in patients divided by genotype.
The logistic regression statistics (Alu-dominant model) revealed that the WNK1 AluYb8 insertion is not associated with blood pressure (P = 0.0880) (Figure 2).
Hypertension is a major public health problem, affecting one in four adults. It is a complex disease, influenced by environmental factors and genetics. Given its high social and economic impact, the need to define genetic features that may predispose to hypertension is strongly felt. Insights into hypertension have been gleaned through the study of rare monogenic hypertension syndromes and of mouse models (Shekarabi et al. 2017). Various blood pressure regulating genes, belonging mainly to the WNK-SPAK-cation-Cl- cotransporter pathways, have been identified. Genes involved in this cascade regulate sodium homeostasis through ion channels in the kidneys and other epithelia. Common variants in these genes are reported to contribute to blood pressure variations in the general population (Tobin et al. 2008; Newhouse et al. 2009; Persu et al. 2016).
In this study we investigated a polymorphic AluYb8 insertion in WNK1 intron 10, hitherto considered a potential contributor to individual variability in blood pressure in different ethnic groups across Europe. In our cohort we found an AluYb8 allele frequency of 16.5%, which is in the range of frequencies observed in 18 different populations from Europe, Asia, and Africa (Putku et al. 2011). The latter authors reported a frequency of WNK1 AluYb8 insertion ranging from 4.8% in Sub-Saharan Africans to 17% in Tatars (Putku et al. 2011). They also looked for an association between the polymorphic AluYb8 WNK1 sequence and susceptibility to arterial hypertension in three different study groups (HYPEST-Estonians, CADCZ-Czech and BRIGHT-British study groups) and in a joint meta-analysis gathering about 3500 patients from the three study cohorts. The authors identified a statistically significant association between blood pressure (either systolic or diastolic) and presence of the AluYb8 polymorphism in the group as a whole. However, when they analysed the populations independently, significance was found in 2/3 cohorts for systolic blood pressure (HYPEST and BRIGHT), and in 1/3 cohorts for diastolic blood pressure (HYPEST). This suggests that ethnicity could influence the association between blood pressure and Alu insertion in WNK1. The same authors noted that the association was gender-specific and was only maintained among women in the joint meta-analysis and for both systolic and diastolic blood pressure in the HYPEST group. These findings are consistent with our preliminary results from this relatively small cohort of patients originating from Krasnoyarsk in Siberia, showing that the polymorphic AluYb8 insertion in WNK1 intron 10 was not associated with arterial hypertension in our male Russian Caucasian population. Failure to replicate the association between blood pressure and polymorphism in this population could be due to genetic heterogeneity across populations, small effect sizes or low power. In future research, we plan to increase cohort size and to enrol both male and female Russian patients. This should enable us to verify whether the findings of Putku and co-workers are also confirmed in the Siberian cohort.
In conclusion, our results indicate that the polymorphism does not increase the risk of hypertension, and were not a major contributor to blood pressure variability in our cohort of Russian males. This means that polymorphic sequence screening is not suitable for evaluating predisposition to hypertension in the Krasnoyarsk region.
We are grateful to all the patients and their families for their invaluable contribution.
About the Authors
MAGI Euregio, Bolzano, Italy
- [email protected]
- Mosterd A, D’Agostino RB, Silbershatz H, Sytkowski PA, et al. (1999) Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med. 340:1221–1227.
- Kannel WB (2000). Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol. 85:251–5.
- Griffin KA (2017) Hypertensive kidney injury and the progression of chronic kidney disease. Hypertension. 70:687–694.
- Lifton R, Gharavi A and Geller D (2001) Molecular mechanisms of human hypertension. Cell 104:545–556.
- Vehaskari V (2007) Developmental origins of adult hypertension: new insights into the role of the kidney. Pediatr Nephrol 22:490–495.
- Huang C-L, Kuo E, Toto RD (2008) WNK kinases and essential hypertension. Curr Opin Nephrol Hypertens 17:133–137.
- Munroe PB, Barnes MR and Caulfield MJ (2013) Advances in blood pressure genomics. Circ Res 112:1365–1379.
- Xu BE, English JM, Wilsbacher JL, Stippec S, et al. (2000) WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 275:16795–16801.
- Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, et al. (2001) Human hypertension caused by mutations in WNK kinases. Science (80- ) 293:1107–1112.
- Delaloy C, Lu JY, Houot AM, Disse-Nicodeme S, et al. (2003) Multiple promoters in the WNK1 gene: One controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 23:9208–9221.
- Tobin MD, Timpson NJ, Wain LV, Ring S, et al. (2008) Common variation in the WNK1 gene and blood pressure in childhood the Avon longitudinal study of parents and children. Hypertension 52:974–979.
- Tobin MD, Raleigh SM, Newhouse S, Braund P, et al. (2005) Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 112:3423–3429.
- Newhouse S, Farrall M, Wallace C, Hoti M, et al. (2009) Polymorphisms in the WNK1 gene are associated with blood pressure variation and urinary potassium excretion. PLoS One.
- Cun Y, Li J, Tang W, Sheng X, et al. (2011) Association of WNK1 exon 1 polymorphisms with essential hypertension in Hani and Yi minorities of China. J Genet Genomics 38:165–171.
- Putku M, Kepp K, Org E, Sõber S, et al. (2011) Novel polymorphic AluYb8 insertion in the WNK1 gene is associated with blood pressure variation in Europeans. Hum Mutat 32:806–814.
- Shekarabi M, Zhang J, Khanna AR, Ellison DH, et al. (2017) WNK kinase signaling in ion homeostasis and human disease. Cell Metab 25:285–299.
- Persu A, Evenepoel L, Jin Y, Mendola A, et al. (2016) STK39 and WNK1 are potential hypertension susceptibility genes in the BELHYPGEN cohort. Medicine (Baltimore) 95:e2968.
- Veríssimo F and Jordan P (2001) WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20:5562–5569.
- Share This